ArticleFrontiers in oncology2026
Disseminated extranodal NK/T-cell lymphoma presenting with bilateral adrenal masses: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a rare case of disseminated extranodal NK/T-cell lymphoma initially presenting with massive bilateral adrenal masses, and to discuss its clinical characteristics, diagnosis, and management based on the case and literature. Methods: A retrospective analysis was performed on the clinical data of a patient admitted to the Department of Urology, The First Affiliated Hospital of Kunming Medical University in June 2023. Results: A 58-year-old female patient presented with right flank and abdominal pain. Imaging revealed massive bilateral adrenal masses. Pathological diagnosis of NK/T-cell lymphoma was confirmed by biopsy, and further staging identified disseminated ENKTCL, stage IV, group A (high-risk). The patient received three cycles of GemOX chemotherapy (gemcitabine + oxaliplatin) but experienced rapid disease progression and died within three months of diagnosis. Conclusion: Extranodal NK/T-cell lymphoma can rarely present initially with bilateral adrenal masses. Its onset is insidious, and the prognosis is extremely poor. When encountering bilateral adrenal masses with atypical imaging features, lymphoma should be considered. Early biopsy to avoid unnecessary surgery, coupled with prompt initiation of systemic treatment through multidisciplinary collaboration, is crucial for improving outcomes in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.